Approval a Significant Milestone Toward Close of Transaction
MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that the Company has received provisional anti-trust approval from the United States Federal Trade Commission (FTC) for the proposed sale of MDS Analytical Technologies to Danaher Corporation (NYSE: DHR).
All other requisite regulatory approvals required for the completion of the acquisition have now been received.
The sale of MDS Analytical Technologies to Danaher, which was announced on September 2, 2009, is expected to close before the end of the first calendar quarter of 2010, subject to the satisfaction of conditions to closing.